Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study

Table 3 Multivariate analysis for CIR, NRM, RFS, and OS in patients with non-DTA genes

Variables	n	CIR		NRM		RFS		OS
Variables	n	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
ddPCR MRD
Negative	98	1.00[Reference]				1.00[Reference]		1.00[Reference]
Positive	52	4.02(1.80–8.96)	< 0.001			2.92(1.51–5.68)	0.002	3.12(1.36–7.15)	0.007
Remission status at time of HSCT							0.052		0.366
CR1	102	1.00[Reference]		1.00[Reference]		1.00[Reference]		1.00[Reference]
≥CR2	26	2.44(0.93–6.40)	0.071	2.41(0.27–21.30)	0.430	2.28(1.00-5.23)	0.051	1.30(0.42–4.08)	0.652
No CR	22	1.52(0.58–3.98)	0.390	5.16(0.67-40.00)	0.120	2.27(1.03–5.01)	0.043	1.97(0.77–5.04)	0.157
DRI-R
Low/Intermediate	92	1.00[Reference]		1.00[Reference]		1.00[Reference]		1.00[Reference]
High/Very high	58	3.39(1.41–8.14)	0.006	5.78(0.68–49.30)	0.110	4.16(1.86–9.34)	0.001	4.00(1.44–11.13)	0.008

Abbreviations ddPCR, droplet digital PCR; MRD, measurable residual disease; CIR, cumulative incidence of relapse; NRM, non-relapse mortality; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CR, complete remission; CR1, first complete remission; CR2, second complete remission; DRI-R, refined disease risk index

ISSN: 1479-5876